MUDr. Dana Maňasková


Vyhledávání na medicinman.cz
 

Apixaban

Direct anticoagulants (DOAC)

  • Associated with less calcification and coronary plaque progression in previous trials
    • Don’t interfere with vitamin K metabolism
  • 12-month effects of apixaban vs rivaroxaban on atherosclerotic plaque characteristics and vascular morphology in patients with atrial fibrillation
  • Assessed by quantitative coronary computed tomographic angiography (CCTA)

Approaches to the choice of anticoagulant therapy in the treatment of patients with combination of atrial fibrillation with coronary heart disease or peripheral atherosclerosis: Potential of apixaban

  • July 2018Rational Pharmacotherapy in Cardiology 14(3):441-450
  • DOI:10.20996/1819-6446-2018-14-3-441-450

Subanalysis of the ARISTOTEL randomized clinical trial

  • High profile of efficacy and safety of apixaban in patients with AF
    • Depending on the presence of CHD, PAD, concomitant use of ASA
  • Benefits of apixaban over warfarin for reducing the risk of stroke/systemic embolism, total mortality and the risk of bleeding in a subgroup of CHD patients
    • Are just as obvious as in the general population of the ARISTOTLE study
    • And in the subgroup of patients without CHD
  • Treatment with apixaban, both in the subgroup of patients taking ASA, and a subgroup of patients without ASA
    • Is accompanied by a lower risk of strokes and systemic embolism
    • Lower incidence of major bleeding
  • Risk of stroke or systemic embolism was similar in patients with AF and PAD randomized to the apixaban group or to the warfarin group, as well as in patients with AF without PAD
  • Patients with AF and PAD who received apixaban or warfarin had a similar incidence of major bleeding or clinically significant minor bleeding.

Apixaban COMPASS trial

  • The group treated with rivaroxaban combined with aspirin, the primary outcome (cardiovascular death,
stroke, and myocardial infarction) occurred significantly less frequently than in the group treated only withaspirin.
  • Significantly higher number of bleedings was observed.
  • In the subgroup of patients with peripheral artery disease
    • A significant reduction of the incidence of amputations was shown
  • Outcomes of the COMPASS trial might be a breakthrough in the treatment of coronary and peripheral atherosclerosis.
  • file:///C:/Users/dana.manaskova/Downloads/82319-296321-1-PB.pdf
O úroveň výše

Poslední aktualizace: 11. 12. 2023 23:26:51